GeNeuro announced on Monday that an independent committee had recommended the continuation of its Phase 2 trial in Covid long after reviewing data on 90 patients treated for three months.

Based on the interim analysis of efficacy and safety data, the independent data monitoring committee recommended continuing the trial without any modifications, the biopharmaceutical company said in a press release.

GeNeuro points out that the review covered unmasked data from the first 90 patients after three months of treatment.

The trial recruited 203 patients from 14 clinical centers in Switzerland, Spain and Italy, all affected by post-Covid neurological syndromes.

All these individuals tested positive for the presence of W-ENV in their blood, a protein suspected of playing a key role in the persistence of inflammation and in the patients' neurological symptoms.

The study is designed to assess the efficacy and safety of temelimab treatment in terms of improving measures of fatigue and cognitive impairment, with initial results expected in June 2024.

Copyright (c) 2023 CercleFinance.com. All rights reserved.